SCHEMBL4142007

SCHEMBL4142007

CC(C)C[C@H](NC(=O)c1cc2c(s1)CCC2)C(=O)NCCCCNS(=O)(=O)c1ccc(F)cc1C(F)(F)F

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CAPN1 P07384 2/20 0.43
HPGD P15428 2/20 0.42
TRPV4 Q9HBA0 1/20 0.41
ALDH1A1 P00352 5/20 0.41
TP53 P04637 1/20 0.41
MAPK1 P28482 1/20 0.41
KDM4E B2RXH2 3/20 0.41
POLB P06746 2/20 0.41
TDP1 Q9NUW8 2/20 0.41
NPC1 O15118 2/20 0.38
RAB9A P51151 2/20 0.38
CYP1A2 P05177 2/20 0.38
CYP2C19 P33261 2/20 0.38
CYP2C9 P11712 1/20 0.38
CTSL P07711 4/20 0.37
CTSS P25774 2/20 0.37
CTSK P43235 2/20 0.37
NPY5R Q15761 3/20 0.36
MEN1 O00255 2/20 0.36
GAA P10253 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5446412 0.89 TRPV4 (0.49) CAPN1HPGDTRPV4ALDH1A1TP53
SCHEMBL4129008 0.85 TRPV4 (0.57) CAPN1TRPV4RAB9ACTSSCTSK
SCHEMBL5435388 0.83 TRPV4 (0.57) CAPN1TRPV4RAB9ACTSSCTSK
SCHEMBL4131294 0.80 CAPN1 (0.47) CAPN1CTSLCTSS
SCHEMBL4130510 0.80 CAPN1 (0.47) CAPN1CTSLCTSSCTSK
SCHEMBL4139220 0.80 CAPN1 (0.47) CAPN1TRPV4CTSLCTSSCTSK
SCHEMBL4142003 0.79 CAPN1 (0.34) CAPN1HPGDALDH1A1KDM4ENPC1
SCHEMBL4128166 0.79 CAPN1 (0.46) CAPN1CTSLCTSS
SCHEMBL4133234 0.79 CAPN1 (0.46) CAPN1POLBNPC1RAB9A
SCHEMBL13872588 0.79 CAPN1 (0.46) CAPN1CTSLCTSS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090105259-A1 Acyclic 1,4-Diamines and Uses Thereof SMITHKLINE BEECHAM CORPORATION 2009-04-23 US claimed
US-20090105259-A1 Acyclic 1,4-Diamines and Uses Thereof SMITHKLINE BEECHAM CORPORATION 2009-04-23 US disclosed
US-20090105259-A1 Acyclic 1,4-Diamines and Uses Thereof SMITHKLINE BEECHAM CORPORATION 2009-04-23 US disclosed
US-20090105259-A1 Acyclic 1,4-Diamines and Uses Thereof SMITHKLINE BEECHAM CORPORATION 2009-04-23 US disclosed
WO-2007030761-A2 ACYCLIC 1,4-DIAMINES AND USES THEREOF SMITHKLINE BEECHAM CORPORATION (US) 2007-03-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105259-A1 Acyclic 1,4-Diamines and Uses Thereof TRPV4, TRPC4, TRPV1 CAPN1 2031/4885HPGD 1044/4885TRPV4 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.